What are the main side effects of using Linagliptin?

From the Guidelines

Linagliptin is generally well-tolerated, but its main side effects include pancreatitis, hypersensitivity reactions, and increased risk of acute pancreatitis, although the overall frequency of pancreatitis with its use is not greater than in patients with diabetes using other agents 1.

Common Side Effects

• The dipeptidyl peptidase (DPP-4) inhibitors, such as linagliptin, decrease the breakdown of the incretin hormones, and improve both fasting and post-prandial glucose levels.
• All DPP-4 inhibitors, including linagliptin, can be used in CKD patients, but some may need downward dose adjustments.

Serious Side Effects

• Pancreatitis is a potential side effect of linagliptin, although the overall frequency is not greater than in patients with diabetes using other agents 1.
• Hypersensitivity reactions, such as angioedema, have been reported with the use of DPP-4 inhibitors, including linagliptin.

Special Considerations

• Linagliptin does not require dose adjustment in patients with renal impairment, making it a suitable option for patients with CKD 1.
• Patients taking linagliptin should be monitored for signs and symptoms of pancreatitis, and the medication should be discontinued if pancreatitis is suspected.

From the Research

Side Effects of Linezolid

The provided studies discuss the side effects of Linezolid, not Linagliptin. However, based on the available information, the main side effects of Linezolid are:

• Gastrointestinal disturbances, such as diarrhea, nausea, and vomiting 2, 3, 4, 5, 6
• Headaches 2, 4, 6
• Myelosuppression, including thrombocytopenia, anemia, and neutropenia 2, 3
• Peripheral neuropathy 3
• Lactic acidosis and relative hypoglycemia 4, 5
• Pancreatitis 4, 5

Rare but Serious Side Effects

Some rare but serious side effects of Linezolid include:

• Reversible myelosuppression associated with long treatments (more than 28 days) 3
• Severe normocytic anemia and mild leukopenia and thrombocytopenia 3
• Linezolid-induced pancreatitis associated with lactic acidosis and relative hypoglycemia 4, 5

Monitoring and Treatment

It is recommended to monitor patients receiving extended durations of Linezolid therapy for adverse effects, including:

• Periodic monitoring of lactate, arterial blood gas, and blood glucose 5
• Complete blood counts should be monitored weekly in patients receiving Linezolid for more than 14 days 2
• Treatment should be discontinued if there is evidence of myelosuppression 2